Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Rcv Gmbh & Co. Kg

Polymun Scientific Immunbiologische Forschung Gmbh

Engenes Biotech Gmbh

Erber Aktiengesellschaft

Reingard Grabherr

Hermann W Katinger

Gerd Schatzmayr

Eva Maria Binder

Gerald Striedner

Wulf-Dieter Moll

Doris Hartinger

Johannes Grillari

Erik Nilsson

Karl Bayer

Juergen Mairhofer

Monika Wilde

Irene Pfaffenzeller

Stefan Heinl

Jurgen Mairhofer

Jürgen Mairhofer

Karin Griessler

The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to methods of increasing the expression level of a protein of interest of a bacterial host cell in a production process. The invention relates particularly to improving the capacity of a bacterial host cell to express a protein of interest by expressing a phage protein during the production process which inhibits growth of the bacterial host cell. Decoupling growth of the bacterial host cell of manufacturing of the protein of interest during the production process reduces (i) the metabolic burden, (ii) oxygen demand, (iii) metabolic heat development, and (iv) avoids stress response caused by heterologous protein expression and thereby increases the capacity of a host cell to produce the protein of interest. The present invention also relates to uses of the host cell for protein expression, cell culture technology, and more specifically to culturing host cells to produce a protein of interest.

Uncoupling growth and protein production

A host-vector system that uses the RNA-based copy number control mechanism of ColE1-type plasmids for regulating the expression of a marker gene allows for antibiotic-free selection of plasmids and is useful for production of plasmid DNA and recombinant proteins.

Host-vector system antibiotic-free ColE1 plasmid propagation

The present invention relates to cell-regulatory proteins and to nucleotide sequences encoding said proteins wherein the proteins have been found to be potential tumor and/or senescense markers useful for medical diagnostics and additionally having therapeutical potential as well as antiapoptotic properties useful for improving cell viability in cell culture technology. The invention further relates to antibodies directed against the cell-regulatory proteins and to their use in medical diagnostics and therapy. The invention further relates to methods for the manufacture and application of the cell-regulatory proteins and of the corresponding nucleotide sequences.

Tumor and senescence marker

In an expression vector having a ColE1 replication system, the homology of the RNAI and RNAII of the ColE1 origin of replication to uncharged tRNAs is modified mutations in the coding region of the RNAI gene and corresponding mutations in the RNAII gene. The mutation results in one or more base exchanges in loop 1 and/or loop 2 and/or loop 3 of RNAI and RNAII. In methods using this vector for producing recombinant proteins, plasmid copy number is stably maintained. In methods for plasmid production, high plasmid copy numbers can be obtained.

Expression vectors with modified ColE1 origin of replication for control of plasmid copy number

Growing community of inventors

Vienna, Austria

Reingard Grabherr